Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to “Hold”

Zacks Research lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a hold rating in a report released on Monday morning,Zacks.com reports.

TBPH has been the topic of several other reports. Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. Finally, HC Wainwright raised their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $21.83.

Theravance Biopharma Stock Up 1.2%

Shares of NASDAQ:TBPH opened at $16.49 on Monday. The stock has a market cap of $850.06 million, a price-to-earnings ratio of 7.50 and a beta of 0.17. Theravance Biopharma has a 52-week low of $10.42 and a 52-week high of $21.03. The business has a 50-day moving average price of $16.42 and a 200-day moving average price of $17.50.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The company had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, equities analysts anticipate that Theravance Biopharma will post 1.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the sale, the senior vice president directly owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.65% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC grew its holdings in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. Creative Planning grew its holdings in Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 842 shares during the period. State of Wyoming grew its holdings in Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,019 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Theravance Biopharma by 6.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 1,020 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.